Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On May 5, 2020, BioSig Technologies, Inc. (the “Company”) issued a press release announcing that Dennis Purcell was appointed to the board of directors of its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc. (“ViralClear”). A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

On May 7, 2020, the Company issued a press release announcing that Michael Schmertzler was appointed to the board of directors of ViralClear. A copy of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.